Adam Scott Levy sold $5.4M of MLYS
CFO and Secretary at Mineralys Therapeutics, Inc.. 119,524 shares at an average of $44.88, traded Nov 11, 2025, filed Nov 13, 2025.
Score components
- +22RoleCFO
- +25Trade size$5.4M at market
- +20Share of holdings soldSold 86% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001933414-25-000152, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2025 | MOption exercise Common Stock | +20,547 | $10.20 | $210k | 53,814 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Common Stock | +34,414 | $16.00 | $551k | 88,228 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Common Stock | +44,079 | $14.25 | $628k | 132,307 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Common Stock | +6,613 | $15.44 | $102k | 138,920 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -1,015 | $42.00 | $43k | 137,905 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -11,295 | $41.87 | $473k | 126,610 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -1,561 | $42.68 | $67k | 125,049 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -12,952 | $41.65 | $539k | 112,097 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -8,485 | $42.34 | $359k | 103,612 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -4,142 | $43.50 | $180k | 99,470 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -8,456 | $45.18 | $382k | 91,014 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -38,900 | $45.93 | $1.8M | 52,114 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -32,718 | $46.88 | $1.5M | 19,396 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Stock Optionderivative | -20,547 | $0.00 | $0 | 135,674 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Stock Optionderivative | -34,414 | $0.00 | $0 | 20,662 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Stock Optionderivative | -44,079 | $0.00 | $0 | 91,592 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Stock Optionderivative | -6,613 | $0.00 | $0 | 4,888 | Nov 13, 2025 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 46Moderate | MLYSbuy Mineralys Therapeutics, Inc. | Ra Capital Management, L.p. director | $8.8M 369,000 shares | +7% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $11k 417 shares | -1% | |
| 4Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $543k 20,406 shares | -23% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $58k 2,171 shares | -3% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $12k 417 shares | -1% | |
| 9Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $570k 20,404 shares | -36% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.